The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Open accessAbstract
BACKGROUND: The status of human epidermal growth factor receptor type 2 (HER2) in breast-cancer cells predicts clinical outcomes in women who receive adjuvant anthracycline-based chemotherapy. We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both. METHODS: We randomly selected 1500 women from 3121 women with node-positive breast cancer who had been randomly assigned to receive doxorubicin (60, 75, or 90 mg per square meter of body-surface area) plus cyclophosphamide (600 mg per square meter) for four cycles, followed by four cycles of paclitaxel (175 mg per square meter) or observation. Tissue blocks from 1322 of these 1500 women were available. Immunohistochemical analyses of these tissue specimens for HER2 with the CB11 monoclonal antibody against HER2 or with a polyclonal-antibody assay kit and fluorescence in situ hybridization for HER2 amplification were performed. RESULTS: No interaction was observed between HER2 positivity and doxorubicin doses above 60 mg per square meter. HER2 positivity was, however, associated with a significant benefit from paclitaxel. The interaction between HER2 positivity and the addition of paclitaxel to the treatment was associated with a hazard ratio for recurrence of 0.59 (P=0.01). Patients with a HER2-positive breast cancer benefited from paclitaxel, regardless of estrogen-receptor status, but paclitaxel did not benefit patients with HER2-negative, estrogen-receptor-positive cancers. CONCLUSIONS: The expression or amplification, or both, of HER2 by a breast cancer is associated with a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin (<60 mg per square meter) plus cyclophosphamide in node-positive breast cancer, regardless of estrogen-receptor status. Patients with HER2-negative, estrogen-receptor-positive, node-positive breast cancer may gain little benefit from the administration of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationCitron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Self-citationAdjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Self-citationc-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Self-citationReporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Self-citationerbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1346 · Cited by 612
Self-citationDose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, Wood, W. C., Weiss, R. B., Ferree, C. R., Muss, H. B., Green, M. R., Norton, L., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1205 · Cited by 577
Self-citationDose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301801 · Cited by 577
Self-citationDose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.852 · Cited by 484
Mass, R. D., Press, M. F., Anderson, S., Cobleigh, M. A., Vogel, C. L., Dybdal, N., Leiberman, G., & Slamon, D. J. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.026 · Cited by 359
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
Bacus, S. S., Gudkov, A. V., Lowe, M., Lyass, L., Yung, Y., Komarov, A. P., Keyomarsi, K., Yarden, Y., & Seger, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204062 · Cited by 358
Yamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Self-citationTrastuzumab and chemotherapeutics: drug interactions and synergies.
Pegram, M. D., Lopez, A. M., Konecny, G., & Slamon, D. (2000) · PubMed · Cited by 174
HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer
Konecny, G., Thomssen, C., Lück, H., Untch, M., Wang, H.-J., Kuhn, W. C., Eidtmann, H., Bois, A. D., Olbricht, S., Steinfeld, D., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh198 · Cited by 156
Leo, A. D., Chan, S. Y. T., Paesmans, M., Friedrichs, K., Pintér, T., Cocquyt, V. F. J., Murray, E., Bodrogi, I., Walpole, E. T., Lespérance, B., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000036783.88387.47 · Cited by 137
Yu, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90277-5 · Cited by 62
p53 expression and resistance against paclitaxel in patients with metastatic breast cancer
Schmidt, M., Bachhuber, A., Victor, A., Steiner, E., Mahlke, M., Lehr, H., Pilch, H., Weikel, W., & Knapstein, P. G. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0430-1 · Cited by 46
Sjöström, J., Collan, J., von Boguslawski, K., Franssila, K., Bengtsson, N., Mjaaland, I., Malmström, P., Østenstad, B., Wist, E., Valvere, V., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00403-8 · Cited by 41
Gonzalez-Angulo, A. M., Krishnamurthy, S., Yamamura, Y., Broglio, K. R., Pusztai, L., Buzdar, A. U., Hortobágyi, G. N., & Esteva, F. J. (2004) · Cancer · doi:10.1002/cncr.20348 · Cited by 27
Ibrahim, E. M., Tulbah, A. M., Ezzat, A. A., Ajarim, D. S., Rahal, M. M., Weshi, A. N. E., & Sörbris, R. (2002) · Medical Oncology · doi:10.1385/mo:19:1:15 · Cited by 12
Cited by
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Self-citationAlbain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Self-citationRoss, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Metadata
- Authors
- Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., Henderson, I. C., Norton, L., Winer, E. P., Hudis, C. A., Ellis, M. J., & Berry, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-11
- Volume
- 357
- Issue
- 15
- Pages
- 1496-1506
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2091205535
- Cited by
- 608
- References
- 30
- FWCI
- 38.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.